Cell Therapy Improves Outcomes in Heart Failure
A clinical trial conducted at the University of Louisville has shown for the first time that heart failure treatments using cells derived from the patient’s own bone marrow and heart resulted in improved quality of life and reduced major adverse cardiac events for patients after one year.
“This is a very important advance in the field of cell therapy and in the management of heart failure. It suggests that a treatment, given only once, can produce long-term beneficial effects on the quality of life and prognosis of these patients,” said Roberto Bolli, director of the UofL Institute of Molecular Cardiology, who led the study at UofL. “The results pave the way for a larger, Phase 3 trial of cell therapy in heart failure.”
The results of the CCTRN CONCERT-HF Trial were published in the European Journal of Heart Failure. The Phase 2, randomized, placebo-controlled trial, funded by NIH National Heart, Lung and Blood Institute, was conducted by the Cardiovascular Cell Therapy Research Network, a network of clinical trial researchers involved in cell therapy for heart disease that includes UofL. UofL led enrollment in the study, accounting for 25% of the 125 trial participants.